4.10.1.3Vertical

Asthma & Pulmonary Allergy Programs

Practices managing asthma and pulmonary allergy conditions.

Market snapshot

These figures describe Allergy & Immunology (4.10.1), the segment that Asthma & Pulmonary Allergy Programs sits within — not Asthma & Pulmonary Allergy Programs on its own.

FragmentationConsolidatingEstimate

Within Offices of Physicians (NAICS 621111); the Census Bureau does not split physician offices by specialty, so allergy and immunology is not separately sized.

Business model & economics

Revenue model

Testing, immunotherapy, and biologic-infusion reimbursement

Key economics

Recurring revenue
High

recurring immunotherapy visits

EBITDA margin
18–28%
Capex intensity
Low

Characteristics

  • Recurring in-office immunotherapy revenue.
  • Rising allergy/asthma prevalence and biologics.
  • Early MSO and PE roll-up interest.

M&A deal context

Deal activityModerate

Who’s acquiring

  • Emerging allergy MSO platforms
  • PE-backed consolidators
  • Multispecialty acquirers

What’s driving deals

  • Emerging allergy roll-up.
  • Allergy/asthma and biologics demand.
  • Recurring immunotherapy economics.

Find Asthma & Pulmonary Allergy Programs acquisition targets

Search Acquisera’s index for companies classified under Asthma & Pulmonary Allergy Programs (4.10.1.3) and build a targeted deal pipeline.

Search companies